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ABSTRACT
AENGEVAEREN, V. L., D. H. F. GOMMANS, H.-J. DIEKER, J. TIMMERMANS, F. W. A. VERHEUGT, J. BAKKER, M. T. E.
HOPMAN, M.-J. DE BOER, M. A. BROUWER, P. D. THOMPSON, M. J. M. KOFFLARD, G. E. CRAMER, and T. M. H. EIJSVOGELS.
Association between Lifelong Physical Activity and Disease Characteristics in HCM.Med. Sci. Sports Exerc., Vol. 51, No. 10, pp. 1995–2002,
2019. Purpose: Hypertrophic cardiomyopathy (HCM) is characterized by inappropriate left ventricular (LV) wall thickness. Adaptations to ex-
ercise can occasionallymimic certainHCMcharacteristics. However, it is unclear whether physical activity affects HCMgenotype expression and
disease characteristics. Consequently, we compared lifelong physical activity volumes between HCM gene carriers with and without HCM phe-
notype, and compared disease characteristics among tertiles of physical activity in phenotypic HCM patients.Methods:We enrolled n = 22 ge-
notype positive/phenotype negative (G+/P−) HCM gene carriers, n = 44 genotype positive/phenotype positive (G+/P+) HCM patients, and
n = 36 genotype negative/phenotype positive (G−/P+) HCMpatients. Lifelong physical activity was recorded using a questionnaire and quan-
tified as metabolic equivalent of task hours per week. Results:We included 102 participants (51 ± 16 yr, 49% male). Lifelong physical ac-
tivity volumes were not different between G+/P+ and G+/P− subjects (16 [10–29] vs 14 [6–26] metabolic equivalent of task‐hours per week,
P = 0.33). Among phenotypic HCM patients, there was no difference in LV wall thickness, mass, and late gadolinium enhancement across
physical activity tertiles. Patients with the highest reported physical activity volumes were younger at the time of diagnosis (tertile 1:
52 ± 14 yr, tertile 2: 49 ± 15 yr, tertile 3: 41 ± 18 yr; P = 0.03), and more often had a history of nonsustained ventricular tachycardia
(4% vs 30% vs 30%, P = 0.03). Conclusions: Lifelong physical activity volumes are not associated with genotype-to-phenotype tran-
sition in HCM gene carriers. We also found no difference in LV wall thickness across physical activity tertiles. However, the most active
HCM patients were younger at the time of diagnosis and had a higher arrhythmic burden. These observations warrant further exploration
of the role of exercise in HCM disease development. Key Words: EXERCISE, CARDIAC MAGNETIC RESONANCE IMAGING,
GENOTYPE, HYPERTROPHIC CARDIOMYOPATHY
Hypertrophic cardiomyopathy (HCM) is the most com-mon inheritable cardiomyopathy and is characterizedby inappropriate left ventricular (LV) wall thickness.
Exercise training is associated with a reduced incidence of car-
diovascular morbidity and mortality (1), but can also increase
LV wall thickness dependent on dose and type of exercise (2).
These adaptations to exercise can occasionally mimic the
HCM phenotype (3).
Recent studies suggested that exercise may accelerate the
development of cardiac complications in individuals with ge-
netic mutations. For example, humans with a genetic predispo-
sition for arrhythmogenic right ventricular cardiomyopathy
(ARVC) (4–6) and a physically active lifestyle had accelerated
appearance (younger age at diagnosis) and progression of dis-
ease. Animal models of ARVC confirmed that exercise accel-
erates ARVC phenotype in mutation carriers (7,8). HCM
sarcomere mutations increase the energy cost of contraction
and impair resting myocardial energetics (9–12), potentially
Address for correspondence: Vincent Laurens Aengevaeren, M.D., Department of
Physiology (392), Radboud University Medical Center, P.O. Box 9101, 6500 HB
Nijmegen, the Netherlands; E-mail: Vincent.Aengevaeren@radboudumc.nl.
G. E. C. and T. M. H. E. are equal author contributions.
Submitted for publication December 2018.
Accepted for publication March 2019.
Supplemental digital content is available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF versions
of this article on the journal’s Web site (www.acsm-msse.org).
0195-9131/19/5110-1995/0
MEDICINE & SCIENCE IN SPORTS & EXERCISE®
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health,
Inc. on behalf of the American College of Sports Medicine. This is an
open-access article distributed under the terms of the Creative Commons
Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND),
where it is permissible to download and share the work provided it is properly
cited. The work cannot be changed in any way or used commercially without
permission from the journal.
DOI: 10.1249/MSS.0000000000002015
1995
C
LIN
IC
A
L
SC
IEN
C
ES
leading to neuroendocrine activation (13) and subsequent hy-
pertrophy and fibrosis (14). During exercise, this energetic im-
pairment is further exacerbated (9) and may consequently
accelerate HCM disease progression.
To explore the relationship between physical activity and
HCM phenotype expression, we compared physical activity
volumes between HCM gene carriers (G+) with a positive
(P+) and negative (P−) HCM phenotype (G+/P+ vs G+/P−).
Furthermore, we compared disease characteristics across
tertiles of lifelong physical activity among phenotypic
HCM patients (G+/P+ and G−/P+).
METHODS
Study population. Subjects were participants of a Dutch
multicenter cohort study: the Biomarkers, Exercise Stress
Testing, and mRi to Obtain New insiGhts in Hypertrophic
CardioMyopathy Study (i.e., the BE STRONG HCM study).
Enrollment took place between April 2008 and January 2014
in two outpatient clinics (Radboud University Medical Center
and Albert Schweitzer Hospital, the Netherlands) that perform
mutation screening, repeated echocardiography cardiac mag-
netic resonance (CMR) imaging, clinical follow-up, and cas-
cade screening. In short, in this study, biomarkers, exercise
stress testing, and magnetic resonance imaging (MRI) charac-
teristics were assessed in phenotypic HCM patients and HCM
gene carriers (15). Adult HCM patients and gene carriers were
invited to participate. HCM patients had to fulfill the diagnos-
tic criteria for HCM according to prevailing guidelines
(16,17). Patients with echocardiographic evidence of LV hy-
pertrophy (maximal wall thickness ≥15 or ≥13 mm in case
of an identifying gene mutation and/or compelling factors as-
sociatedwith HCM)without another cardiac or systemic cause
at the time of HCM diagnosis were eligible for participation.
The diagnosis was verified by a careful case-by-case chart re-
view (D.H.F.G., G.E.C.). In case of a discrepancy between the
treating physician and the investigators, the opinion of a third
independent reviewer was decisive (M.J.M.K.). As part of
routine clinical evaluation, all patients underwent a 12-lead
electrocardiogram (ECG), 24-h ECG Holter, and echocardio-
gram. HCM patients with known coronary disease (previous
myocardial infarction, >50% stenosis on coronary angiogram,
previous percutaneous coronary intervention, previous coro-
nary artery bypass grafting), stroke, aortic valve stenosis,
previous septal reduction therapy, or renal impairment (de-
fined as estimated glomerular filtration rate <30 mL·min−1)
were not eligible for study participation. Phenotype-negative
HCM gene carriers were detected based on screening ac-
cording to a cascade strategy and thus represented family
members of HCM patients. Participants were not necessarily
athletes but represented a “normal” HCM cohort from the
general population and were thus not detected by an athletic
screening program.
For the present explorative post hoc analysis, we enrolled
1) genotype positive/phenotype negative (G+/P−) HCM gene
carriers, 2) genotype positive/phenotype positive (G+/P+)
HCM patients, and 3) genotype negative/phenotype positive
(G−/P+) HCM patients. The study complies with the Declara-
tion of Helsinki, and the protocol was approved by the local
ethical committees and conducted accordingly. Participants
provided written informed consent.
Study protocol. At the time of participation in the cohort
study, symptoms and medical therapy were recorded, and risk
factors for cardiovascular disease (18) and sudden cardiac
death (SCD) (16) were scored. A blood sample was drawn for
assessment of creatinine and cardiac troponin T concentrations.
Eligible patients were invited to the hospital for CMR imaging.
CMR imagingwas performed, as previously prescribed (15), on
a 1.5-T cardiac CMR system Philips Achieva (Philips Health-
care, Best, the Netherlands) or Siemens Avanto (Siemens
Healthcare, Erlangen, Germany) according to local protocol.
All images were acquired with ECG gating and during repeated
breath-holds of 10–15 s. For the assessment of LVmorphology
and function, cine imaging was performed using a steady-state
free precession sequence. T1-weighted inversion-recovery im-
aging was performed to assess late gadolinium enhancement
(LGE) 10 min after the administration of 0.2 mmol·kg−1 con-
trast medium (Dotarem; Guerbet, Gorinchem, the Netherlands).
Physical activity. Participants reported their lifelong
physical activity history per decade including type of exercise,
years, days per week, weeks per year, duration of the sessions,
and the intensity level at which they performed every exercise
or sport. The questionnaire (Supplemental Digital Content 1,
Lifelong Physical Activity Questionnaire, http://links.lww.
com/MSS/B590) that we used to quantify lifelong physical
activity volumes was adapted from the concept described by
Friedenreich et al. (19). We have previously used a similar ques-
tionnaire in the Nijmegen Exercise Study (20), interviewing indi-
viduals with cardiovascular diseases, risk factors, and healthy
controls. Both sports-related exercise and physical activity during
transportation (walking and cycling) were included.We assigned
a metabolic equivalent of task (MET) for all activities (21) and
calculated the physical activity volume by multiplying the
MET score by the reported physical activity volume (session du-
ration  frequency/week) and weeks of practice per year and
years of practice. Average lifetime physical activity exposure
was calculated in MET-hours per week, as previously described
(22). Physical activity intensity was divided into light (<3 MET,
not reported), moderate (3–6 MET), and vigorous (>6 MET) in-
tensity (23), based on the MET scores of the specific activities.
We also separately calculated physical activity volumes before
and after the HCM phenotype diagnosis to look specifically at
the effects of physical activity before diagnosis and to compare
prediagnosis and postdiagnosis physical activity volumes. Aver-
age physical activity between age 12 yr and the age at study par-
ticipation was termed lifelong physical activity, whereas physical
activity between age 12 yr and the age at HCM diagnosis was
termed prediagnosis physical activity.
Data analysis. All parameters were visually inspected for
normality, checked for kurtosis and skewness, and tested
with Shapiro–Wilk normality tests. Continuous variables are
http://www.acsm-msse.org1996 Official Journal of the American College of Sports Medicine
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presented as means ± SD or medians (interquartile ranges).
Statistical analyses were performed with IBM SPSS Statistics
20.0 (IBM Corp, Armonk, NY). Statistical significance was
assumed at P < 0.05.
HCM gene carriers. Physical activity volumes were
compared between G+/P+ (prediagnosis physical activity) and
G+/P− individuals (lifelong physical activity) to assess whether
habitual physical activity and exercise training relate to HCM
phenotype expression. Comparisons between groups were made
with use of the Student’s t-test orMann–WhitneyU-test, which-
ever appropriate. Dichotomous variables were compared
using a χ2 or Fisher exact test, whichever appropriate.
Phenotypic HCM patients. To explore the association
between lifelong physical activity and disease characteristics,
we compared LV function, LV wall thickness, LV mass, the
presence of LGE, troponin levels, age at diagnosis, and 24-h
ECG recordings across lifelong physical activity tertiles in
phenotypic HCM patients (G+/P+ and G−/P+) using one-
way ANOVA and Kruskal–Wallis. Within-subject compari-
son of physical activity volumes before and after diagnosis
was done using a related-samples Wilcoxon signed rank test.
Finally, comparisons with regard to lifelong physical activity
volumes were made according to prespecified HCM sub-
groups. Phenotypic HCM patients were divided according to
LGE presence and LV thickness (<20 and ≥20 mm).
RESULTS
Study population. For this explorative post hoc analysis,
we invited 131 possible participants, of whom 102 (49%male;
Fig. 1) completed the questionnaire, including 22 G+/P−
HCM gene carriers, 44 G+/P+ HCM patients, and 36 G−/P+
HCM patients. The 29 possible participants not included de-
clined participation (n = 14) or did not complete the lifelong
physical activity history questionnaire (n = 15). Subject char-
acteristics were not different between included and excluded
individuals (data not shown). Mean age ± SD of the studied
population was 51 ± 16 yr. Median volumes [and interquartile
range] of lifelong physical activity and sports-related exercise
were 14 [8–22] MET·h·wk−1 and 7 [2–14] MET·h·wk−1, re-
spectively. Among 102 genetically tested individuals, 66 had
a pathogenic HCM mutation, of which n = 49 (74%) had mu-
tations in the cardiac myosin-binding protein (MYBPC3),
n = 13 (20%) in the β-myosin heavy chain (MYH7), and
n = 4 (6%) in other genes.
HCM gene carriers. Age at diagnosis of G+/P+ individ-
uals (43 ± 15 yr) was similar to age at study participation of
G+/P− individuals (40 ± 11 yr, P = 0.37). G+/P+ patients were
more often male (52% vs 27%, P = 0.05; Table 1). Echocardio-
graphic parameters, ECG abnormalities, and CMR parameters
differed between G+/P+ and G+/P− individuals as expected
and according to their disease classification (Table 1).
FIGURE 1—Flowchart of study design. MRI could not be performed in 13 participants because of noncompatible implantable cardiac defibrillators/
pacemakers (n = 8), for logistic reasons (n = 3), because of claustrophobia (n = 1), or because of dental prosthesis (n = 1).
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With regard to our study question in HCM gene carriers,
there was no difference in physical activity volumes between
G+/P+ and G+/P− (16 [10–29] vs 14 [6–26] MET·h·wk−1,
P = 0.33; Table 1) or sports-related physical activity volumes
(8 [2–17] vs 6 [2–16] MET·h·wk−1, P = 0.84; Table 1). The in-
tensity at which sports were performed did not differ between
G+/P+ and G+/P− individuals (Table 1). Distribution of phys-
ical activity over time did not differ between G+/P+ and G+/P−
individuals (Fig. 2A).
Phenotypic HCM patients. G+/P+ HCM patients were
younger when diagnosed with HCM and more often had a
family history of SCD and LGE on MRI as compared with
G−/P+ HCM patients (Table, Supplemental Digital Content 2,
Participant characteristics of phenotypic HCM patients ac-
cording to genotype status, http://links.lww.com/MSS/B591).
The per decade reported physical activity volumes were
consistently different across physical activity tertiles as
displayed in Figure 2B. Furthermore, physical activity volumes
were lower after HCM diagnosis (15 [9–24] MET·h·wk−1
prediagnosis vs 7 [0–19]MET·h·wk−1 postdiagnosis, P < 0.001).
With regard to our study question in phenotypic HCM pa-
tients, there was no difference in LV morphology, wall thick-
ness, mass, presence of LGE, and troponin levels across
physical activity tertiles (Table 2). The prevalence of T-wave
TABLE 1. Physical activity and participant characteristics of HCM gene carriers according to phenotype.
Phenotype+ (n = 44) Phenotype− (n = 22) P
Physical activitya
Physical activity, MET·h·wk−1 16 [10–29] 14 [6–26] 0.33
Physical activity during adolescenceb, MET·h·wk−1 21 [12–31] 18 [7–25] 0.17
Sports-related physical activitya
Exercise volume, MET·h·wk−1 8 [2–17] 6 [2–16] 0.84
Moderate intensity, h·wk−1 0.3 [0–1.4] 0.3 [0–2.0] 0.47
Vigorous intensity, h·wk−1 0.2 [0–0.9] 0.3 [0–0.7] 0.63
Transportation physical activitya
Active transportation, MET·h·wk−1 9 [4–14] 7 [4–11] 0.26
Participant characteristics
Agea, yr 43 ± 15 40 ± 11 0.37
Sex, male (%) 23 (52) 6 (27) 0.054
Cardiovascular risk factors
Hypertension, n (%) 15 (34) 2 (9) 0.03*
Current smoker, n (%) 8 (18) 5 (23) 0.75
Dyslipidaemia, n (%) 9 (21) 0 (0) 0.02*
Diabetes, n (%) 1 (2) 0 (0) >0.99
Recent creatinine, μmol·L−1 83 ± 17 69 ± 10 0.002*
Systolic blood pressure, mm Hg 128 ± 21 115 ± 18 0.02*
Heart rate, bpm 70 ± 12 74 ± 11 0.23
History of atrial fibrillation, n (%) 5 (11) 0 (0) 0.16
Framingham 10-yr heart risk, % 10 [3–22] 3 [1–6] 0.002*
Elevated troponin, >14 ng·L−1, n (%) 8 (19) 0 (0) 0.04*
Risk factors for SCD
Aborted cardiac arrest/sustained VT, n (%) 1 (2) 0 (0) >0.99
Family history of SCD, n (%) 12 (27) 2 (9) 0.12
Syncope, n (%) 1 (2) 1 (5) >0.99
Nonsustained VT (Holter), n (%) 12 (29) 0 (0) 0.02*
Abnormal blood pressure response, n (%) 7 (16) 1 (5) 0.25
Maximal wall thickness ≥30 mm, n (%) 1 (2) 0 (0) >0.99
Symptoms
Chest pain, n (%) 8 (18) 1 (5) 0.25
Dyspnea (NYHA class ≥ II), n (%) 20 (45) 0 (0) <0.001*
Therapy
β-Blocker, n (%) 21 (48) 0 (0) <0.001*
Calcium antagonist, n (%) 6 (14) 0 (0) 0.17
Echocardiography
LV outflow tract gradient ≥30 mm Hg, n (%) 6 (14) 0 (0) 0.09
Systolic anterior motion mitral valve, n (%) 15 (34) 1 (5) 0.01*
Left atrial diameter, mm 43 [39–50] 39 [34–40] 0.001*
ECG
T-wave inversion, n (%) 16 (36.4) 2 (9.1) 0.019*
Q-waves, n (%) 5 (11.4) 0 (0) 0.10
LV hypertrophy, n (%) 1 (2.3) 0 (0) 0.48
Right bundle branch block, n (%) 2 (4.5) 0 (0) 0.31
CMR imaging n = 36 n = 21
Maximal LV wall thickness, mm 18 ± 5 11 ± 3 <0.001*
LV end-diastolic volume, mL 186 ± 36 167 ± 29 0.04*
LV ejection fraction, % 59 ± 8 61 ± 7 0.29
LV mass index, g·m−2 64 [51–78] 43 [36–47] <0.001*
LGE present, n (%) 24 (69) 2 (10) <0.001*
LGE extent, % of LV mass 3 [0–10] 0 [0–0] <0.001*
Data are presented as mean ± SD, n (%), or median [interquartile range].
aUntil diagnosis for P+ and until participation for P− individuals.
bAdolescence is age 12–30 yr.
*P < 0.05.
NYHA, New York Heart Association functional classification; VT, ventricular tachycardia.
http://www.acsm-msse.org1998 Official Journal of the American College of Sports Medicine
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inversion, Q-waves, and LV hypertrophy did not differ on
12-lead ECG recordings across tertiles, whereas the prevalence
of bundle branch blocks was lowest in tertile 3. We did observe
a difference across tertiles regarding nonsustained ventricular
tachycardia (NSVT), with NSVT being significantly more
prevalent on 24-h ECG recordings in physically active patients
(physical activity: 4% [tertile 1] vs 30% [tertile 2] vs 30%
[tertile 3], P = 0.03). We observed a graded decrease in the
prevalence of an outflow tract gradient >30 mm Hg across
tertiles. The most active patients had a higher prevalence of a
positive family history for SCD. Finally, the most active indi-
viduals were significantly younger when they received their di-
agnosis (52 ± 14 vs 49 ± 15 vs 41 ± 18, P = 0.03; Table 2).
Lastly, lifelong physical activity volumes did not differ be-
tween phenotypic HCM patients with LV wall thickness
≥20 and <20mm (17 [11–23] vs 13 [5–22],P = 0.10), whereas
phenotypic HCM patients with LGE had higher lifelong phys-
ical activity volumes compared with those without LGE
(16 [10–23] vs 11 [5–19] MET·h·wk−1, P = 0.046).
DISCUSSION
We explored the relationship between physical activity and
HCM phenotype expression. We found no differences in
physical activity characteristics between HCM gene carriers
with and without HCMphenotype.We also found no evidence
of increased LV wall thickness, LV mass, or elevated cardiac
troponin levels among the most active phenotypic HCM pa-
tients. However, we did find a younger age at diagnosis and
higher prevalence of a history of NSVT in the most active phe-
notypic HCM patients. Furthermore, lifelong physical activity
levels were higher in phenotypic HCM patients with LGE.
These findings suggest that lifelong physical activity volumes
are not associated with genotype-to-phenotype transition in
HCM gene carriers or LV wall thickness in HCM patients.
However, given our findings of a younger age at diagnosis
and a higher prevalence of ventricular arrhythmias among
the most active phenotypic HCM patients, a potential role of
physical activity in accelerating disease presentation and se-
verity cannot be ruled out.
Transition from genotype to phenotype. To date, the
reasons why gene carriers of sarcomeric mutations show very
heterogeneous expression of disease remain ill-defined (24).
In the present analysis, average physical activity volumes were
comparable among HCM gene carriers with and without
HCM phenotype, suggesting that exercise does not increase
genotype-to-phenotype transition in genetically susceptible in-
dividuals. On the other hand, few of our subjects were athletes
and the majority engaged primarily in aerobic physical activi-
ties. Hence, the dose and type of physical activity may have
been too low to induce detrimental morphological changes in
our cohort. Also, aerobic exercise training produces only small
increases in LV wall thickness, whereas strength training pro-
duces considerably greater increases in LV wall thickness (2).
Consequently, although we did not find a relationship be-
tween primarily aerobic physical activity and HCM genotype-
to-phenotype transition, we cannot exclude the possibility that
more intense aerobic or strength training could provoke onset
of the HCM phenotype in genetically susceptible individuals.
Physical activity and disease characteristics. Ad-
aptations to exercise can occasionally mimic HCM LV hyper-
trophy (3). However, we did not find a difference in LV wall
thickness across physical activity tertiles. This is in line with
previous studies showing that LV wall thickness did not
change in HCM patients after 16 wk of moderate-intensity ex-
ercise training (25) and was not different between phenotypic
HCM athletes and nonathletes (26).
Higher physical activity volumes were related to a younger
age at diagnosis, which could indicate that physical activity
produced symptoms that prompted the diagnosis or that phys-
ical activity accelerated disease progression. Similar observa-
tions were reported in exercising individuals with ARVC
(4,6), in which exercise is known to enhance disease severity.
We also found increased NSVT prevalence in the most ac-
tive phenotypic HCM patients, which could indicate that
activity might adversely impact disease progression. Exercise
FIGURE 2—Distribution of physical activity volumes over time of HCM gene carriers according to phenotype status (A) and of phenotypic HCM patients
according to tertiles of lifelong physical activity volume (B). Individuals included per decade differ because of the heterogeneity in age of the participants,
and numbers are shown below x-axis. Physical activity shown in panel A is prediagnosis physical activity for G+/P+ and lifelong physical activity forG+/P−.
Physical activity shown in panel B is lifelong physical activity. Data are shown as median with interquartile range.
LIFELONG PHYSICAL ACTIVITY AND HCM Medicine & Science in Sports & Exercise® 1999
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might lead to a temporary supply-demand mismatch due to
the inappropriate LV hypertrophy and might subsequently in-
duce myocardial ischemia and development of myocardial fi-
brosis. The observation that phenotypic HCM patients with LGE
had higher lifelong physical activity volumes compared with
those without LGE supports the hypothesis that high volumes
of exercisemay be harmful to someHCMpatients. Alternatively,
more activity may increase the frequency of NSVTwithout al-
tering the underlying disease. Exercise-induced ischemia may
provide the trigger for potentially life-threatening arrhythmias,
as has been suggested by the observation that HCM is a com-
mon cause of SCD among athletes during sports participation
(27). Future studies including larger populations of HCM pa-
tients are needed to better define the association between exer-
cise characteristics and disease severity.
Individuals in the more active tertiles less often had LV out-
flow tract pressure gradients ≥30 mm Hg. It is possible that
subjects with lower LV outflow tract gradients were better able
TABLE 2. A comparison of disease characteristics across tertiles of physical activity among phenotypic HCM patients (G+/P+ and G−/P+).
Physical Activity, MET·h·wk−1
T1 (n = 27) T2 (n = 26) T3 (n = 27) P
Physical activity volume
Total physical activity, MET·h·wk−1 4 [2–9] 14 [13–16] 25 [22–34] <0.001*
During adolescence, MET·h·wk−1 8 [2–11] 22 [17–28] 34 [23–42] <0.001*
Prediagnosis, MET·h·wk−1 5 [2–10] 15 [13–18] 29 [23–42] <0.001*
Postdiagnosis, MET·h·wk−1 0 [0–4] 9 [0–16] 21 [12–33] <0.001*
Sports-related, MET·h·wk−1 1 [0–3] 8 [4–11] 15 [12–24] <0.001*
Transportation, MET·h·wk−1 2 [1–6] 6 [4–10] 11 [8–13] <0.001*
Participant characteristics
Age, yr 58 ± 14 54 ± 15 49 ± 17 0.10
Sex, male, n (%) 14 (52) 15 (58) 15 (56) 0.91
Age at diagnosis, yr 52 ± 14a 49 ± 15 41 ± 18 0.03*
Pathogenic mutation present, n (%) 12 (44) 14 (54) 18 (67) 0.26
Cardiovascular risk factors
Hypertension, n (%) 12 (44) 13 (50) 12 (44) 0.90
Current smoker, n (%) 6 (22) 5 (19) 5 (19) 0.94
Dyslipidaemia, n (%) 7 (26) 6 (23) 6 (23) 0.95
Diabetes, n (%) 2 (7) 2 (8) 0 (0) 0.46
Recent creatinine, μmol·L−1 84 ± 15 90 ± 18 81 ± 15 0.13
Systolic blood pressure, mm Hg 136 ± 23 134 ± 24 126 ± 24 0.25
Heart rate, bpm 75 ± 14 76 ± 14 70 ± 14 0.28
History of atrial fibrillation, n (%) 4 (15) 5 (19) 3 (11) 0.68
Framingham 10-yr heart risk, % 16 [12–28] 14 [4–29] 7 [3–23] 0.09
Elevated troponin, >14 ng·L−1, n (%) 5 (20) 8 (33) 3 (12) 0.17
Risk factors for SCD
Aborted cardiac arrest/sustained VT, n (%) 2 (7) 0 (0) 0 (0) 0.33
Family history of SCD, n (%) 2 (7) 3 (12) 9 (33) 0.04*
Syncope, n (%) 0 (0) 1 (4) 0 (0) 0.33
Nonsustained VT (Holter), n (%) 1 (4) 7 (30) 8 (30) 0.03*
Abnormal BP response, n (%) 5 (19) 3 (12) 5 (19) 0.80
Maximal wall thickness ≥30 mm, n (%) 0 (0) 1 (4) 1 (4) 0.77
Symptoms
Chest pain, n (%) 3 (11) 4 (15) 5 (19) 0.80
Dyspnea (NYHA class ≥II), n (%) 15 (56) 13 (50) 11 (41) 0.55
Therapy
β-Blocker, n (%) 15 (56) 14 (54) 12 (44) 0.68
Calcium antagonist, n (%) 4 (15) 3 (12) 4 (15) >0.99
ICD, n (%) 2 (7) 1 (4) 5 (19) 0.26
Echocardiography
LV outflow tract gradient, mm Hg 21 [6–50] 7 [6–14] 7 [5–13] 0.05
LV outflow tract gradient ≥30 mm Hg, n (%) 10 (39) 4 (15) 1 (4) 0.01*
Systolic anterior motion mitral valve, n (%) 15 (58) 9 (35) 8 (30) 0.09
Left atrial diameter, mm 45 [39–50] 43 [38–51] 42 [36–47] 0.39
ECG
T-wave inversion, n (%) 11 (41) 15 (58) 11 (41) 0.40
Q-waves, n (%) 1 (4) 5 (19) 1 (4) 0.08
LV hypertrophy, n (%) 1 (4) 1 (4) 1 (4) 1.00
Bundle branch block, n (%) 2 (7) 4 (15) 0 (0) 0.014
CMR imaging
Maximal LV wall thickness, mm 17 ± 4 19 ± 5 17 ± 5 0.31
Maximal wall thickness ≥20 mm, n (%) 4 (17) 8 (35) 6 (29) 0.40
LV end-diastolic volume, mL 189 ± 45 175 ± 41 187 ± 37 0.45
LV end-systolic volume, mL 81 ± 31 72 ± 22 73 ± 24 0.47
LV ejection fraction, % 58 ± 9 59 ± 7 62 ± 7 0.32
LV mass index, g·m−2 60 [52–87] 74 [56–96] 64 [59–73] 0.57
LGE present, n (%) 10 (44) 14 (61) 14 (67) 0.27
LGE extent, % of LV mass 0 [0–6] 3 [0–12] 3 [0–7] 0.23
Data are presented as mean ± SD, n (%), or median [interquartile range].
aPost hoc test, significantly different from tertile 3.
*P < 0.05.
BP, blood pressure; ICD, implantable cardioverter/defibrillator; VT, ventricular tachycardia.
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to perform higher volumes of exercise. Alternatively, a physi-
cally active lifestyle could improve LV outflow tract pressure
gradients among phenotypic HCM patients because 2 and
6 months of exercise training reduced markers of HCM dis-
ease severity (i.e., hypertrophy, fibrosis, myocyte disarray) in
a murine HCM model (28). However, these explanations do
not align with a landmark study showing an increase in LV out-
flow tract pressure gradients among HCM patients completing
16 wk of moderate-intensity exercise training (25). Future stud-
ies should further explore the effects of controlled exercise
training on HCM disease development in humans.
Clinical implications. In the general population, exercise
drastically reduces the risk of cardiovascular diseases and
events (1). Individuals with HCM are often advised not to par-
ticipate in most competitive sports, in line with current guide-
lines (29). A recent study randomized individuals with HCM
to an exercise (moderate-intensity exercise training) or usual
activity group for 16 wk (25). HCM patients in the exercise
group successfully increased their V̇O2 peak (from 21.3 to
22.7 mL·min−1·kg−1), which aligns with a previous observa-
tion that patients with HCM improved their exercise test time
and NewYork Heart Association functional class with cardiac
rehabilitation (30). However, 32% of the HCM patients in the
exercise group versus 23% of the HCM patients in the usual
activity group experienced NSVT during the study protocol
(25). Although exercise training was not associated with an in-
creased occurrence of arrhythmias (no P value given), this
trend is in line with our finding of increased NSVT in the most
active individuals.
Short-term intervention studies primarily demonstrated
beneficial exercise-induced adaptations in HCM patients, but
we found a younger age at diagnosis, a higher prevalence of
NSVT, and higher lifelong physical activity volumes in indi-
viduals with LGE, which questions the long-term health ef-
fects of exercise training in this patient population. A recent
study found that vigorous exercise was not related to patholog-
ical LV hypertrophy and ventricular arrhythmias in HCM
(26). However, athletic HCM patients were distinctly younger
(51 ± 14 yr vs 57 ± 13 yr, P = 0.01) and more frequently dem-
onstrated LGE (73% vs 53%,P = 0.09) comparedwith nonath-
lete HCM patients, which is consistent with our findings. Italian
athletes with HCM had a similar risk of symptoms and events
during 9 ± 6-yr follow-upwhether they continued performing ex-
ercise or interrupted their exercise training (31). However, it is
unclear how these groups differed based on baseline characteris-
tics, risk due to disease severity and follow-up time.
In conclusion, although exercise is a potent medicine for the
general population, it remains unclear whether individuals
with HCM may miss the health benefits of a physically active
lifestyle due to exercise restriction policies in current guide-
lines or whether they are protected from potential detrimental
effects of exercise training on disease progression.
Future studies should focus on long-term outcomes for indi-
viduals with HCM and physical activity characteristics, with
specific attention for a potential earlier onset of disease, and in-
crease in LGE and arrhythmic burden. For example, the Life-
style and Exercise in HCM study is an ongoing prospective
observational study (32), enrolling patients with HCM across
a range of activity levels, which is expected to provide novel
findings in the near future.
Limitations. This study is observational and retrospective,
making it impossible to separate the cause versus effect rela-
tionships. However, it is extremely difficult, if not impossible,
to randomize HCM gene carriers to exercise training or a con-
trol condition to study the long-term effects of physical activ-
ity on HCM progression and severity. Our study may also
suffer from selection bias due to our study design and inclu-
sion. Furthermore, our results depended on subjects recalling
their lifelong physical activity volumes, but potential bias
should have affected all participants similarly. Finally, our
study (and other studies on this topic (26,31)) suffers from a
limited sample size but adds valuable information to the cur-
rently limited data available on the association between exer-
cise and HCM.
CONCLUSIONS
We found no association between lifelong physical activity
volumes and HCM phenotype among HCM gene carriers. We
also found no difference in LV wall thickness across physical
activity tertiles. These findings suggest that lifelong physical ac-
tivity volumes are not associated with genotype-to-phenotype
transition in HCM gene carriers or LV wall thickness in HCM
patients. However, the most active HCM patients were younger
when diagnosed and more often had a history of NSVT, and
HCM patients with LGE had higher physical activity volumes.
These observations warrant further exploration of the role of ex-
ercise in HCM disease development.
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